文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

血小板抑制的创伤性脑损伤患者接受血小板输注后神经外科干预需求与死亡率降低

Traumatic brain injury patients with platelet inhibition receiving platelet transfusion demonstrate decreased need for neurosurgical intervention and decreased mortality.
PubMed 文献 · J Trauma Acute Care Surg · 2022-01-01
一句话结论TBI伴血小板抑制患者输注1单位血小板可改善ADP/AA抑制,ADP改善者神经外科干预需求降低,作者认为可能获益。

该回顾性研究在一级创伤中心纳入2019年12月至2020年12月的453例TBI患者,按实践管理指南入院时行TEG-PM检测,ADP或AA抑制>60%者输注1单位血小板并复查。147例因ADP和/或AA抑制接受血小板,其中107例复查;输注后ADP(p<0.0001)、AA(p<0.0001)和MA(p=0.0002)均显著改善。330例未服用抗血小板药的TBI患者中50.9%存在ADP和/或AA抑制;入院时AA或ADP抑制者死亡率增加(p=0.0108);ADP随血小板输注改善者神经外科干预需求减少(p=0.0182)。作者认为TEG-PM可用于TBI初始评估以评估血小板功能障碍并提供预后信息。

要点

  • TBI患者入院时ADP或AA抑制>60%者,按指南输注1单位血小板并复查TEG-PM。
  • 输注血小板后ADP(p<0.0001)、AA(p<0.0001)和MA(p=0.0002)均显著改善。
  • 330例未服抗血小板药的TBI患者中50.9%存在ADP和/或AA抑制。
  • 入院时AA或ADP抑制者死亡率增加(p=0.0108)。
  • ADP随血小板输注改善者神经外科干预需求减少(p=0.0182)。

适用人群与场景

  • 2019年12月至2020年12月在一级创伤中心就诊的TBI患者,入院时均行血小板映射检测。
  • 未服用抗血小板药物的TBI患者中50.9%(330例中)存在ADP和/或AA抑制。

诊断标准与关键阈值

  • 采用血栓弹力图血小板映射(TEG-PM;Haemonetics)评估血小板功能抑制程度,通过ADP和AA通路。
  • ADP或AA抑制>60%定义为血小板抑制,触发输注1单位血小板并复查血小板映射。

处置流程与药物剂量

  • 入院时对所有TBI患者行血小板映射检测。
  • 若ADP或AA抑制>60%,输注1单位血小板,并复查血小板映射检测。
  • 研究期间方案依从率为66.5%。

红旗征与不能漏的情况

  • 入院时AA或ADP抑制提示死亡率增加(p=0.0108)。

研究设计与关键结果

  • 回顾性研究,一级创伤中心,2019年12月至2020年12月共13个月,纳入453例TBI患者,方案依从率66.5%。
  • 147例因ADP和/或AA抑制接受血小板输注,其中107例输注后复查TEG-PM。
  • 输注血小板后ADP(p<0.0001)、AA(p<0.0001)和MA(p=0.0002)均显著改善。
  • 330例未服用抗血小板药物的TBI患者中,50.9%显示ADP和/或AA抑制。
  • 入院时存在AA或ADP抑制者死亡率增加(p=0.0108)。
  • ADP随血小板输注改善者神经外科干预需求减少(p=0.0182)。

证据类型、等级与局限

  • 证据类型:回顾性研究;证据等级:治疗/管理, level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,TBI伴血小板抑制患者可能从输注血小板纠正血小板功能障碍中获益。
  • 作者认为,TEG-PM可纳入TBI患者初始评估,以评估血小板功能障碍并提供预后信息,可能指导治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Platelet dysfunction is known to occur in patients with traumatic brain injury (TBI), and the correction of platelet dysfunction may prevent hemorrhagic progression in TBI. Thromboelastography with platelet mapping (TEG-PM; Haemonetics) evaluates the degree of platelet function inhibition through the adenosine diphosphate (ADP) and arachidonic acid (AA) pathways. We hypothesized that ADP and AA inhibition would improve with the transfusion of platelets in patients with TBI.

METHODS: A retrospective review was conducted at a Level I trauma center of all patients presenting with TBI from December 2019 to December 2020. Per a practice management guideline, a platelet mapping assay was obtained on all patients with TBI upon admission. If ADP or AA was found to be inhibited (>60%), the patient was transfused 1 unit of platelets and a repeat platelet mapping assay was ordered. Demographic data, laboratory values, and outcomes were analyzed.

RESULTS: Over the 13-month study period, 453 patients with TBI underwent TEG-PM with a protocol adherence rate of 66.5% resulting in a total of 147 patients who received platelets for ADP and/or AA inhibition; of those, 107 underwent repeat TEG-PM after platelets were administered. With the administration of platelets, ADP (p < 0.0001), AA (p < 0.0001), and MA (p = 0.0002) all significantly improved. Of 330 patients with TBI not taking antiplatelet medications, 50.9% showed inhibition in ADP and/or AA. If AA or ADP inhibition was noted on admission, mortality was increased (p = 0.0108). If ADP improved with platelet administration, the need for neurosurgical intervention was noted to decrease (p = 0.0182).

CONCLUSION: Patients with TBI and platelet inhibition may benefit from the administration of platelets to correct platelet dysfunction. Thromboelastography with platelet mapping may be implemented in the initial workup of patients presenting with TBI to assess platelet dysfunction and provide prognostic information, which may guide treatment.

LEVEL OF EVIDENCE: Therapeutic / Care Management, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Miles MVP, Hicks RC, Parmer H, et al. Traumatic brain injury patients with platelet inhibition receiving platelet transfusion demonstrate decreased need for neurosurgical intervention and decreased mortality. J Trauma Acute Care Surg. 2022. PMID: 35320155. doi:10.1097/TA.0000000000003516

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。